Document Detail


Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
MedLine Citation:
PMID:  23272794     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This article reviews the pharmacological profile and published efficacy and tolerability/safety data of iloperidone, asenapine and lurasidone, the most recent atypical antipsychotics to be approved in the USA for the treatment of schizophrenia. All three agents are similar in terms of overall efficacy and low propensity for clinically significant weight gain or adverse changes in glycemic or lipid profile. However, these agents differ from one another in terms of formulations, pharmacokinetics, and dosing and nonmetabolic adverse effect profile. For each drug, comparative and real-world effectiveness studies are lacking, as are effectiveness and safety data in elderly, young and pregnant/nursing patients. As such, the exact place of iloperidone, asenapine and lurasidone within the broader antipsychotic armamentarium is currently difficult to establish.
Authors:
William V Bobo
Related Documents :
6994484 - Emit assays for five major anticonvulsant drugs. an evaluation of adaptations to two di...
23991674 - Construction of multifunctional modules for drug discovery: synthesis of novel thia/oxa...
23566104 - Elucidating a relationship between conformational sampling and drug resistance in hiv-1...
16710584 - Drug rash with eosinophilia and systemic symptoms induced by valproate and carbamazepin...
24498794 - Paclitaxel loaded niosome nanoparticle formulation prepared via reverse phase evaporati...
24819644 - Cutaneous targets in drug-induced reactions.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Expert review of clinical pharmacology     Volume:  6     ISSN:  1751-2441     ISO Abbreviation:  Expert Rev Clin Pharmacol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-31     Completed Date:  2013-05-14     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  101278296     Medline TA:  Expert Rev Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  61-91     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA. william.v.bobo@vanderbilt.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antipsychotic Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Drug Approval
Heterocyclic Compounds with 4 or More Rings / adverse effects,  pharmacokinetics,  therapeutic use*
Humans
Isoindoles / adverse effects,  pharmacokinetics,  therapeutic use*
Isoxazoles / adverse effects,  pharmacokinetics,  therapeutic use*
Piperidines / adverse effects,  pharmacokinetics,  therapeutic use*
Schizophrenia / drug therapy*,  metabolism
Thiazoles / adverse effects,  pharmacokinetics,  therapeutic use*
Grant Support
ID/Acronym/Agency:
MH087747/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Heterocyclic Compounds with 4 or More Rings; 0/Isoindoles; 0/Isoxazoles; 0/Piperidines; 0/Thiazoles; 133454-47-4/iloperidone; 22IC88528T/lurasidone; JKZ19V908O/Asenapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  KCNE genetics and pharmacogenomics in cardiac arrhythmias: much ado about nothing?
Next Document:  Internalized stigma among patients with schizophrenia in Ethiopia: a cross-sectional facility-based ...